Industriepark Mechelen Noord I, Zone L
Generaal De Wittelaan 11 A
559 articles with Galapagos NV
Galapagos NV announced its first quarter 2022financial results, a year-to-date business updateand its outlook for the remainder of 2022.
Galapagos NV announces that theproposed resolutions presented at the extraordinary and annual shareholders’ meetingswere approved, including the implementation of a one-tier governance structure.
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
Galapagos NV reports that Gilead Sciences K.K., Eisai Co., Ltd. and EA Pharma Co., Ltd. announced the approval by the Japanese Ministry of Health, Labour and Welfare, of a second indication for Jyseleca, a once-daily, oral, JAK1 preferentialinhibitor, for the treatment of patients with moderate-to-severe active ulcerative colitis.
Galapagos publishes 2021 annual report and announces extraordinary and annual shareholders’ meetings
Galapagos NV published its annual report for the financial year 2021 and announces extraordinary and annual shareholders’ meetings to be held sequentially on Tuesday 26 April 2022 at 1:00p.m. and 2:00p.m., respectively, at the registered office of the Company.
Galapagos issued 95,500 new ordinary shares on 18 March 2022, for a total capital increase of €2,159,600.00.
Galapagos NV presents financial results 2021, reviews key events forthe company, and provides outlook for 2022.
Galapagos provides further insights into the treatment of ulcerative colitis at the European Crohn’s and Colitis Organization (ECCO) annual congress
Galapagos NV will present data at the European Crohn’s and Colitis Organization annual congress taking place 16-19 February 2022.
Galapagos NV has appointed Dr. Paul Stoffelsas as its new chief executive officer, replacing Onno van de Stolpe who is retiring.
Galapagos NV (Euronext & NASDAQ: GLPG) is pleased to announce the appointment of Dr. Paul Stoffelsas Chief Executive Officer (CEO),effective April 1, 2022.
JYSELECA®▼ (FILGOTINIB) LICENSED FOR THE TREATMENT OF ADULT PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS IN GREAT BRITAIN
Galapagos NV (Euronext & Nasdaq: GLPG) announced today that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted a marketing authorization for Jyseleca®(filgotinib 200mg tablets), as a new treatment for ulcerative colitis (UC) for Great Britain.
Galapagos NV (Euronext & NASDAQ: GLPG) will participate in the40th Annual J.P. Morgan Healthcare Conference on January 10-13, 2022.
Ryvu Therapeutics S.A. announced that the pre-agreed criteria in the Option, License and Research Collaboration Agreement, announced between Ryvu and Galapagos on April 16, 2020, have been achieved and Galapagos has exercised its exclusive option for the program.
Galapagos completes patient recruitment for MANGROVE Phase 2 trial with GLPG2737 in polycystic kidney disease
Galapagos NV (Euronext & NASDAQ: GLPG) announces completion of recruitment in the MANGROVE Phase 2 trial with investigational CFTR inhibitor GLPG2737 in patients with autosomal dominant polycystic kidney disease (ADPKD).
Galapagos NV (Euronext & Nasdaq: GLPG) announced today that the European Commission has granted marketing authorization for Jyseleca®(filgotinib 200mg tablets) for the treatment of adult patients with moderately to severely active ulcerative colitis (UC).
Galapagos NV is pleased to report on itscommercial launch of filgotinib in Europe.The company is moving forward with its revised R&D strategy and operational restructuring announced in May, resulting in a downward adjustment of thecash burn by €50 million.
Galapagos presents new data from the SELECTION Phase 3 program at the United European Gastroenterology Week (UEGW) 2021 congress
Galapagos NV (Euronext & NASDAQ: GLPG) todayannouncedresults of twopost-hoc analyses from the SELECTION and SELECTION LTEstudies, which are part of the investigational clinical program for filgotinib, forthe treatment of patients with moderately to severely activeUC.
Galapagos announces completion of patient enrollment for DIVERSITY Phase 3 study with filgotinib in Crohn’s Disease
Galapagos NV announced randomization of the last patient into the multi-center, globalDIVERSITY Phase 3 study.
Galapagos issued 7,600 new ordinary shares on 20 September 2021, for a total capital increase of €151,787.50.
GALAPAGOS ANNOUNCES POSITIVE CHMP OPINION FOR JYSELECA® (FILGOTINIB) FOR THE TREATMENT OF ADULTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
Galapagos NV today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca